TARA Earnings & Financial Statements
Protara Therapeutics, Inc.
$2.48
-$0.14(-5.34%)
35
Overall
60
Value
18
Tech
28
Quality
Market Cap
$146.56M
Volume
701.41K
52W Range
$2.51 - $7.82
Target Price
$26.57
TARA earnings and financial statements: Protara Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TARA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$64.55M | -$49.15M | -$43.61M | -$67.06M | -$47.49M |
| EBITDA | -$56.00M | -$43.26M | -$53.26M | -$64.57M | -$45.40M |
| Net income | -$57.44M | -$44.60M | -$40.42M | -$65.95M | -$47.25M |
| EPS (diluted) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $209.47M | $181.45M | $78.95M | $113.29M | $172.60M |
| Total liabilities | $13.06M | $14.32M | $10.63M | $11.21M | $10.68M |
| Shareholders’ equity | $196.41M | $167.13M | $68.32M | $102.08M | $161.91M |
| Cash and equivalents | $49.66M | $162.80M | $39.59M | $24.13M | $35.72M |
| Long-term debt | $2.12M | $3.36M | $4.48M | $5.47M | $6.38M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$56.37M | -$35.81M | -$37.56M | -$26.46M | -$34.50M |
| Capital expenditure | -$94.0K | -$63.0K | -$45.0K | -$120.0K | -$596.0K |
| Free cash flow | -$56.46M | -$35.87M | -$37.60M | -$26.58M | -$35.10M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TARA | $2.48 | -5.3% | 701.41K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Protara Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW